Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07647393

Ultrasound Muscle Biomarkers as Predictors of Isometric Quadriceps Muscle Strength and Handgrip in Healthy Adults: an Observational Study

This observational study aims to determine whether ultrasound-derived muscle biomarkers can predict isometric quadriceps muscle strength and handgrip in healthy adults aged 18-89 years.

The main questions it aims to answer are:

* Which ultrasound muscle characteristics are associated with isometric quadriceps muscle strength and handgrip? * Can ultrasound-derived biomarkers be used to develop predictive models of muscle strength in healthy adults?

Participants will undergo:

* Ultrasound assessment of the quadriceps and forearm flexor muscles; * Measurement of isometric quadriceps muscle strength and handgrip using standardized dynamometry protocols; * Assessment of functional capacity, mobility and balance; * Completion of questionnaires related to health status, physical activity, nutrition, fatigue and health-related quality of life.

The study will also assess the reliability of ultrasound measurements and explore the relationship between ultrasound variables, muscle strength, physical function and health-related factors.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Observational

About this study

Peripheral muscle strength is an important determinant of physical function, independence and health outcomes. Reduced quadriceps muscle strength and handgrip have been associated with functional limitations, frailty, hospitalization and mortality. Although muscle ultrasound is increasingly used to assess muscle morphology and quality, its ability to predict muscle strength remains incompletely understood.

The MUSCLE-US study is a monocentre observational study designed to investigate the relationship between ultrasound-derived muscle biomarkers and isometric quadriceps muscle strength and handgrip in healthy adults. Participants aged 18-89 years will be recruited from community settings and stratified by age and sex.

Ultrasound assessments will be performed on the quadriceps and forearm flexor muscles using standardized acquisition procedures. First-order variables (e.g., muscle thickness, cross-sectional area, pennation angle, fascicle length), second-order texture features and higher-order ultrasound biomarkers will be extracted and analysed.

Isometric quadriceps muscle strength and handgrip will be measured using standardized dynamometry protocols. Additional assessments will include functional capacity tests, mobility and balance measures, physical activity, nutritional status, fatigue, dyspnoea, health-related quality of life, lifestyle factors and comorbidity profiles.

The primary objective is to identify ultrasound biomarkers associated with quadriceps muscle strength and handgrip, and to develop predictive models of muscle strength. Secondary objectives include assessment of ultrasound measurement reliability and exploration of relationships between ultrasound biomarkers, muscle strength, physical function and health-related characteristics.

Recruitment, assessor training, ultrasound standardisation procedures and reliability analyses will be conducted during the initial phase of the project, followed by the main recruitment and data collection phase and subsequent statistical modelling and dissemination activities.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults aged 18-89 years.
  • Resident in Spain for at least 5 years.
  • Living independently in the community and able to complete all study assessments.
  • Able to understand and follow verbal instructions in Spanish.
  • Able and willing to provide written informed consent prior to study participation.

Exclusion criteria

  • Neurological, musculoskeletal, or systemic disorders affecting muscle strength or mobility.
  • Recent surgery or acute injury affecting the upper or lower limbs.
  • Recent use of medications affecting the musculoskeletal system (e.g., systemic corticosteroids for >1 week during the previous 6 months or muscle relaxants during the previous week).
  • Cognitive or psychiatric conditions limiting participation.
  • Pregnancy.
  • Recent postpartum period (≤3 months after delivery).
  • Presence of clinically relevant pain, fatigue, physical deconditioning, or functional limitations that may interfere with study procedures or measurement validity.
  • Acute illness at the time of assessment.
  • Uncontrolled hypertension (≥140/90 mmHg).
  • Resting peripheral oxygen saturation ≤90%.
  • Moderate-to-severe pain (Numeric Rating Scale ≥4/10).
  • Any medical condition considered by the investigator to contraindicate study participation.

Treatment and study plan

Primary outcomes

  1. Isometric quadriceps muscle strength

    Time frame: Day 1

    Quadricpes maximal voluntary contraction measured using a handheld dynamometer according to a standardized testing protocol. Peak force will be recorded in kilograms-force (kgf).

  2. Handgrip

    Time frame: Day 1

    Maximal voluntary handgrip measured using a hydraulic hand dynamometer according to the American Society of Hand Therapists protocol. Peak force will be recorded in kilograms-force (kgf).

  3. Ultrasound-derived muscle biomarkers

    Time frame: Day 1

    Muscle ultrasound biomarkers obtained from standardized B-mode ultrasound images of selected quadriceps and forearm muscles. Candidate variables include muscle morphology, architecture, grayscale characteristics and texture-based parameters. The final set of ultrasound-derived biomarkers will be defined following assessor training, protocol standardization and pilot reliability analyses.

Secondary outcomes

  1. Five-repetition sit-to-stand test

    Time frame: Day 1

    Functional capacity assessed by the time required to complete five sit-to-stand repetitions according to standardised procedures. Results will be expressed in seconds. Lower values indicate better lower-limb functional capacity.

  2. One-minute sit-to-stand test

    Time frame: Day 1

    Functional capacity assessed as the number of sit-to-stand repetitions completed in one minute according to standardised procedures. Higher values indicate better functional exercise capacity.

  3. Timed Up and Go test

    Time frame: Day 1

    Mobility and dynamic balance assessed using the Timed Up and Go test. Results will be expressed in seconds. Lower values indicate better mobility and dynamic balance.

  4. Modified Medical Research Council dyspnoea scale

    Time frame: Day 1

    Dyspnoea severity assessed using the modified Medical Research Council dyspnoea scale. Scores range from 0 to 4, with higher scores indicating greater breathlessness.

  5. Modified Borg dyspnoea scale

    Time frame: Day 1

    Perceived breathlessness assessed using the modified Borg dyspnoea scale. Scores range from 0 to 10, with higher scores indicating greater breathlessness.

  6. Dyspnoea-12

    Time frame: Day 1

    Dyspnoea assessed using the Dyspnoea-12 questionnaire. The total score ranges from 0 to 36, with higher scores indicating more severe breathlessness.

  7. Functional Assessment of Chronic Illness Therapy-Fatigue

    Time frame: Day 1

    Fatigue assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. Scores range from 0 to 52, with higher scores indicating less fatigue.

  8. EuroQol 5-Dimension 5-Level

    Time frame: Day 1

    Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D) questionnaire. The index score will be calculated according to the appropriate national value set. Higher scores indicate better health status. Self-rated health assessed using the EQ-5D Visual Analogue Scale. Scores range from 0 to 100, with higher scores indicating better perceived health.

  9. International Physical Activity Questionnaire-short form

    Time frame: Day 1

    Physical activity assessed using the International Physical Activity Questionnaire-short form. Results will be expressed as minutes per week spent in vigorous/moderate/total physical activity, time per week spent walking and hours per day spent in sedentary behaviour (sitting).

  10. Mini Nutritional Assessment-short form

    Time frame: Day 1

    Nutritional status assessed using the Mini Nutritional Assessment-short form. Scores range from 0 to 14, with higher scores indicating better nutritional status.

Other outcomes

  1. Age

    Time frame: Day 1

    Participant age recorded in completed years.

  2. Weight

    Time frame: Day 1

    Participant weight recorded in kilograms.

  3. Height

    Time frame: Day 1

    Participant height recorded in metres.

  4. Body mass index

    Time frame: Day 1

    Body mass index calculated as weight divided by height squared.

  5. Sex

    Time frame: Day 1

    Participant biological sex recorded as female or male.

  6. Systemic inflammation markers

    Time frame: Day 1

    CRP, IL-6, eosinophils, fibrinogen, neutrophil elastase, ESR, KL-6, SP-D, FeNO, IgE, calprotectin, if available, from medical records.

  7. Charlson Comorbidity Index

    Time frame: Day 1

    Comorbidity burden assessed using the Charlson Comorbidity Index. Higher scores indicate greater comorbidity burden.

  8. Anatomical Therapeutic Chemical (ATC) Classification System

    Time frame: Day 1

    Current medication use classified according to the Anatomical Therapeutic Chemical (ATC) Classification System.

  9. Smoking Exposure (pack-year index)

    Time frame: Day 1

    Lifetime smoking exposure quantified using the pack-year index, calculated from self-reported smoking history. A higher pack-year index means greater cumulative exposure to tobacco smoking over lifetime.

  10. Alcohol Use Disorders Identification Test-Consumption

    Time frame: Day 1

    Alcohol consumption assessed using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C). Higher scores indicate greater alcohol consumption and increased risk of hazardous drinking.

Study contacts

Contact information is provided by the study sponsor or research team.

Beatriz Sánchez-Sánchez, PT, Ph.D.

CONTACT

[email protected]

+34 918 85 48 28

Nicola S. Diciolla, PT, Ph.D.

CONTACT

[email protected]

+34 918 85 48 28

Sponsors and collaborators

Lead sponsor

University of Alcala

Other

Registry information

Acronym: MUSCLE-US

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jun 15, 2026
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.